TweeSteden Hospital, Tilburg, the Netherlands.
Neth Heart J. 2010 Sep;18(9):444-50. doi: 10.1007/BF03091812.
Chronic oral anticoagulant treatment is obligatory in patients (class I) with mechanical heart valves and in patients with atrial fibrillation with CHADS2 score >1. When these patients undergo percutaneous coronary intervention with placement of a stent, there is also an indication for treatment with aspirin and clopidogrel. Unfortunately, triple therapy is known to increase the bleeding risk. For this group of patients, the bottom line is to find the ideal therapy in patients with indications for both chronic anticoagulation therapy and percutaneous intervention to prevent thromboembolic complications such as stent thrombosis without increasing the risk of bleeding. (Neth Heart J 2010;18:444-50.).
慢性口服抗凝治疗是强制性的在患者（I 类）机械心脏瓣膜和心房颤动患者 CHADS2 评分>1。当这些患者接受经皮冠状动脉介入治疗与支架置入，也有一个用于阿司匹林和氯吡格雷治疗的适应证。不幸的是，三联疗法已知增加出血风险。对于这群患者，关键是要找到理想的治疗方法在有慢性抗凝治疗和经皮介入治疗适应证的患者中，以预防血栓栓塞并发症，如支架内血栓形成，而不增加出血风险。（Neth Heart J 2010；18:444-50.）。
